James Chih-Hsin Yang, Date: April 29-30, 2017

Slides:

Advertisements

Similar presentations

Asst. Prof. Dr Khomapak Maneewat Faculty of Nursing, Prince of Songkla University, Thailand Chairman of Ceremony.

Advertisements

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

Electronics and Communications Section IT Fest 2016 IET Hong Kong Forum on Mobile Technology and Cloud Development in Hong Kong Date: 19 April 2016 Time:

Big Data Innovations from Hong Kong Academic and Research Institutes 20 April :30pm to 5:30pm.

APEC Conference on the Innovation, Achievement and Sustainable Development in Public Health Emergency Response Systems 10 years after SARS Epidemic July.

Recent Advances in NSCLC Treatment

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

HK-Taipei-Tokyo Trade Conference

Keynote Speaker: John Condeelis, PhD

Hong Kong Orthopaedic Association Adult Joint Reconstruction Chapter

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Cancer Immunotherapy Market: size, trend, share, opportunity analysis & forecast,

Lung Cancer with Unusual Presentation as a Thin-Walled Cyst in a Young Nonsmoker Chou-Chin Lan, MD, Hong-Cheng Wu, MD, Chih-Hsin Lee, MD, Shiu-Feng Huang,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Volume 23, Issue 2, Pages (June 2016)

Characteristics of Hospitalized Patients with Atrial Fibrillation in Taiwan: A Nationwide Observation Cheng-Han Lee, MD, Ping-Yen Liu, MD, PhD, Liang-Miin.

April 10, 2018 Save the Date Passport 2018

Volume 64, Issue 3, Pages (March 2016)

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Advanced Lung Cancers: What's on the Horizon?

Pyogenic Liver Abscess as the Initial Manifestation of Underlying Hepatocellular Carcinoma Yi-Tsung Lin, MD, Chia-Jen Liu, MD, Tzeng-Ji Chen, MD, Te-Li.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Optimal Duration of Anti-TB Treatment in Patients With Diabetes

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer Peter M.

Catheter-based neurosalvage for acute embolic complication during carotid intervention Mao-Shin Lin, MD, Ying-Hsien Chen, MD, Chi-Chao Chao, MD, Cheng-Hsin.

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Katsuyuki Kiura,

International Symposium of Tokyo University of Science, Translational Research (TR) Center —Frontiers in Developmental Strategy for Cancer Therapeutics—

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib Suzanne Jenkins, DPhil, James Chih-Hsin.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study Kaoru Kubota, MD, PhD,

Objective Palliative Prognostic Score Among Patients With Advanced Cancer Yen-Ting Chen, MD, Chih-Te Ho, MD, Hua-Shai Hsu, MD, Po-Tsung Huang, MD, Chin-Yu.

Hsin Hsu Wu, MD, Chang Fu Kuo, MD, PhD, I

Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian.

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

The Hong Kong Geriatrics Society Inter-hospital Geriatric Meeting

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Journal of Thoracic Oncology

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small- Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer Gyo Asai, MD, PhD, Nobuyuki.

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

Value in Health Regional Issues

Meeting Summary of the 12th International Conference on Screening for Lung Cancer: Nara, Japan, April 2005 Kenji Eguchi, MD, PhD, Claudia Henschke, MD,

Volume 151, Issue 3, Pages e1 (September 2016)

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Prognostic Heterogeneity in Multilevel N2 Non-Small Cell Lung Cancer Patients: Importance of Lymphadenopathy and Occult Intrapulmonary Metastases Yukinori.

The Hong Kong Geriatrics Society Inter-hospital Geriatric Meeting

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for.

The Hong Kong Geriatrics Society Inter-hospital Geriatric Meeting

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer:

Lung Cancer with Unusual Presentation as a Thin-Walled Cyst in a Young Nonsmoker Chou-Chin Lan, MD, Hong-Cheng Wu, MD, Chih-Hsin Lee, MD, Shiu-Feng Huang,

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Presentation transcript:

James Chih-Hsin Yang, Date: April 29-30, 2017 Meeting Venue: Auditorium 301, NTUH International Convention Center April 29 Topic Speaker Moderator 01:30-02:00 PM Registration 02:00-02:10 PM Opening Remark Ann-Lii Cheng National Taiwan University Hospital, Taipei, Taiwan Kazuhiko Nakagawa Kindai University Faculty of Medicine, Osaka, Japan 02:10-02:50 PM Recent progress and future perspectives of cancer immunotherapy Yutaka Kawakami, MD, PhD Keio University School of Medicine, Tokyo, Japan James Chih-Hsin Yang, 02:50-03:10 PM Ongoing Japan-Taiwan Phase I Trials: durvalumab plus ramucirumab Chia-Chi (Josh) Lin, MD, PhD James Chih-Hsin Yang 03:10-03:30 PM Ongoing Japan-Taiwan Phase I Trials: atezolizumab plus erlotinib Brigette BY Ma, MBBS, MD Prince of Wales Hospital, Hong Kong, China 03:30-03:50 PM Pharmaceutical Company Pipelines: Boehringer-Ingelheim Gerd Munzert, MD Boehringer Ingelheim Pharma GmbH & Co. KG, XXX, Germany 03:50-04:05 PM Coffee Break 04:05-04:45 PM Exemplification of Drug Development: Nano-liposomal irinotecan (MM398) Li-Tzong Chen, MD, PhD National Health Research Institute, Tainan, Taiwan 04:45-05:05 PM Cancer Immunotherapy Combination: Head and neck cancer Naomi Kiyota, MD, PhD Kobe University Hospital, Kobe, Hyogo, Japan 05:05-05:25 PM Cancer Immunotherapy Combination: Non-small cell lung cancer Hidetoshi Hayashi, MD, PhD 05:25-05:45 PM Pharmaceutical Company Pipelines: Daiichi Sankyo Koichi Akahane MD Daiichi Sankyo, Tokyo, Japan 05:45-05:55 PM Wrap Up on Day One

Date: April 29-30, 2017 Meeting Venue: Auditorium 301, NTUH International Convention Center April 30 Topic Speaker Moderator 07:30-08:00 AM Registration 08:00-08:10 AM Highlight on Day One Chia-Chi (Josh) Lin, MD, PhD National Taiwan University Hospital, Taipei, Taiwan 08:10-08:20 AM Ongoing Japan-Taiwan Phase I Trials: HDM201 Noboru Yamamoto, MD, PhD National Cancer Center Hospital, Tokyo, Japan James Chih-Hsin Yang, 08:20-08:40AM Complete Japan-Taiwan Phase I Trials: sonidegib (LDE225) Yuichi Ando, MD, PhD Nagoya University Hospital, Nagoya, Aichi, Japan Discussant: James Chih-Hsin Yang 08:40-09:00 AM Jih-Hsiang Lee, MD 09:00-09:20 AM Hironobu Minami, MD, PhD Kobe University Hospital, Kobe, Hyogo, Japan 09:20-09:40 AM Pharmaceutical Company Pipelines: Novartis (TBC) 09:40-09:55 AM Coffee Break 09:55-10:15 AM Cancer Immunotherapy Combination: Gastric cancer Toshihiko Doi, MD, PhD (TBC) National Cancer Center Hospital East, Kashiwa, Chiba, Japan 10:15-10:35 AM Cancer Immunotherapy Combination: Colon cancer Hisato Kawakami, MD, PhD Kindai University Faculty of Medicine, Osaka, Japan 10:35-10:55 AM Cancer Immunotherapy Combination: How to select the best cancer immunotherapy combination trials for our patients? Shigehisa Kitano MD, PhD 10:55-11:15 AM Pharmaceutical Company Pipelines: Roche 11:15-11:35 AM Pharmaceutical Company Pipelines: Eli Lilly 11:35-11:50 AM Concluding Remarks Ann-Lii Cheng, MD, PhD Kazuhiko Nakagawa, MD, PhD